Giorgio Valabrega

19PUBLICATIONS
97CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMedical mycologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Feb 26, 2025
Oncolytic Viruses in Ovarian Cancer: Where Do We Stand? A Narrative Review.

Fulvio Borella, Marco Carosso, Maria Pia Chiparo

|Dec 27, 2024
Targeting TOP2A in Ovarian Cancer: Biological and Clinical Implications.

Fulvio Borella, Stefano Fucina, Ylenia Seminara

|Nov 09, 2024
Treatment Strategies for Advanced Endometrial Cancer According to Molecular Classification.

Valentina Tuninetti, Alberto Farolfi, Chiara Rognone

|Nov 02, 2024
Three-dimensional dynamics of mesothelin-targeted CAR.CIK lymphocytes against ovarian cancer peritoneal carcinomatosis.

Federica Galvagno, Valeria Leuci, Annamaria Massa

|Sep 25, 2024
Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial.

Giorgio Valabrega, Matthew A Powell, Sakari Hietanen

|Apr 16, 2024
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design.

Ignace Vergote, Alejandro Perez Fidalgo, Giorgio Valabrega

Pageof 4

Frequent Collaborators

7 joint publications

Valentina Tuninetti

5 joint publications

Fulvio Borella

3 joint publications

Massimo Di Maio

3 joint publications

Stefano Cosma